Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?

Pediatric Blood and Cancer

Volumn 54, Issue 5, 2010, Pages 781-782

  Moreau, Emilie ^a   André, Nicolas ^a,b   Coze, Carole ^a   Padovani, Laetitia ^a   Mercier, Cedric ^b   Ciccolini, Joseph ^b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTIDINE DEAMINASE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; NAVELBINE; RETINOIC ACID; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CASE REPORT; CHILD; CYTIDINE DEAMINASE DEFICIENCY; ENZYME DEFICIENCY; FEMALE; HUMAN; HYPERURICEMIA; HYPOCALCEMIA; KIDNEY FAILURE; LETTER; LIVER TOXICITY; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; NEUTROPENIA; ONCOGENE; PAIN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHOSPHATE BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR LYSIS SYNDROME; TUMOR VOLUME;

ANTIMETABOLITES, ANTINEOPLASTIC; CHILD, PRESCHOOL; CYTIDINE DEAMINASE; DEOXYCYTIDINE; FEMALE; HUMANS; NEUROBLASTOMA; TUMOR LYSIS SYNDROME;

EID: 77950490958     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22427     Document Type: Letter

References (8)

1. Reid JM, Qu W, Safgren SL, et al. Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors. J Clin Oncol 2004;22:2445-2451. (Pubitemid 41115403)
2. Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP, et al. Phase II study of gemcitabine in children with solid tumours of mesenchymal and embryonic origin. Anticancer Drugs 2006;17:859-864. (Pubitemid 44310183)
3. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419-425.
4. Cole PD, Schwartz CL, Drachtman RA, et al. Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: A children's oncology group report. J Clin Oncol 2009;27:1456-1461.
5. Coze C, Hartmann O, Michon J, et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: A report from the French Society of Pediatric Oncology. J Clin Oncol 1997;15:3433-3440. (Pubitemid 27527714)
6. Rampello E, Fricia T, Malaguarnera M. The management of tumor lysis syndrome. Nat Clin Pract Oncol 2006;3:438-447.
7. Kushner BH, LaQuaglia MP, Modak S, et al. Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification. Med Pediatr Oncol 2003;41:80-82. (Pubitemid 41103264)
8. Cicollini J, Dahan L, André N, et al. CDA residual activity in serum is a predictive marker of early severe toxicities after gemcitabine-based chemotherapies. J Clin Oncol 2010;28:160-165.